Aperio Group LLC boosted its stake in shares of Qiagen NV (NASDAQ:QGEN) by 13.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 184,966 shares of the company’s stock after buying an additional 21,973 shares during the period. Aperio Group LLC owned approximately 0.08% of Qiagen NV worth $5,075,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Manning & Napier Advisors LLC raised its position in shares of Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock valued at $133,287,000 after buying an additional 1,470,315 shares during the period. Citadel Advisors LLC bought a new position in Qiagen NV during the second quarter worth approximately $28,145,000. Harris Associates L P raised its position in Qiagen NV by 62.6% in the second quarter. Harris Associates L P now owns 3,331,940 shares of the company’s stock worth $72,670,000 after buying an additional 1,282,240 shares during the last quarter. Exane Asset Management bought a new position in Qiagen NV during the second quarter worth approximately $14,260,000. Finally, Bank of Montreal Can bought a new position in Qiagen NV during the second quarter worth approximately $12,050,000. 57.33% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Qiagen NV (NASDAQ:QGEN)

Qiagen NV (NASDAQ:QGEN) traded up 1.55% during mid-day trading on Tuesday, hitting $27.52. The company had a trading volume of 788,076 shares. The stock has a 50 day moving average price of $26.50 and a 200-day moving average price of $24.83. The stock has a market capitalization of $6.45 billion, a PE ratio of 55.04 and a beta of 1.07. Qiagen NV has a 1-year low of $19.94 and a 1-year high of $28.50.

Qiagen NV (NASDAQ:QGEN) last issued its earnings results on Wednesday, November 2nd. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. The company earned $338.70 million during the quarter, compared to the consensus estimate of $335.46 million. Qiagen NV had a net margin of 8.96% and a return on equity of 9.34%. Qiagen NV’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. On average, analysts forecast that Qiagen NV will post $1.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of United States and international copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/aperio-group-llc-raises-position-in-qiagen-nv-qgen.html.

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $27.00 price target on shares of Qiagen NV in a report on Thursday, November 3rd. Commerzbank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Wednesday, August 31st. Bank of America Corp. raised Qiagen NV from an “underperform” rating to a “neutral” rating in a report on Thursday, November 3rd. Zacks Investment Research lowered Qiagen NV from a “buy” rating to a “hold” rating in a report on Wednesday, October 19th. Finally, HSBC raised Qiagen NV from a “hold” rating to a “buy” rating in a report on Monday, August 1st. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.60.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Receive News & Stock Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related stocks with our FREE daily email newsletter.